Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry

Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee

“…Similar outcomes have been replicated at other academic-and community-based proton centers (77,78) where consolidation proton therapy has primarily been used for young patients with mediastinal HL and bulky disease (78). Among 40 patients with HL treated with consolidation proton involved-site RT and prospectively followed up in the Proton Collaborative Group Registry, there were 3 recurrences (2-year relapse-free survival rate, 85%) in a cohort predominantly composed of patients with unfavorable stage I or II disease (45%) or stage III or IV disease (33%).…”

“…Among 40 patients with HL treated with consolidation proton involved-site RT and prospectively followed up in the Proton Collaborative Group Registry, there were 3 recurrences (2-year relapse-free survival rate, 85%) in a cohort predominantly composed of patients with unfavorable stage I or II disease (45%) or stage III or IV disease (33%). Two recurrences were in field within bulky mediastinal disease treated to 21 Gy (RBE); one was superior to the CTV and would have been outside the photon field as well (77). In the largest study to date, comprising 135 patients prospectively followed up who had HL treated with protons (including 40 in the aforementioned Proton Collaborative Group Registry), the 3-year progression-free survival rate was 92% (78).…”

Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines

“…1 Additionally, the lack of marginal relapses that are feared when using a highly conformal therapy like proton treatment has made it an appealing treatment. [22][23][24] Because the magnitude of dosimetric benefit varies significantly depending on the specific case, each case must be considered individually, and the potential benefit from proton use should be weighed against the availability of the treatment (need to travel), out-of-pocket costs if insurance coverage is denied, resources required in terms of medical and physics staff, and the potential uncertainties associated with proton therapy.…”

<p>Proton Therapy For Lymphomas: Current State Of The Art</p>

“…Some clinical reports were subsequently published, with most of them focusing on HL patients with mediastinal involvement. The Proton Collaborative Group Registry reported on a cohort of 50 patients treated with consolidation proton ISRT and followed-up prospectively (median follow-up time: 21 months) 22. Most patients were adults (64%), with a high prevalence of mediastinal involvement (93%) and of bulky lesions (65%).…”